How to Prepare Your Health Now for a Possible Retatrutide Prescription
How to Prepare Your Health Now for a Possible Retatrutide Prescription If you’re following retatrutide as a possible future treatment, you’ve probably done the math: TRIUMPH-1 reads out in the next few months, the NDA filing follows later in 2026, FDA review runs through 2027, and commercial availability is at least mid-to-late 2027 in the […]
How to Read a GLP-1 Trial Result Without Getting Misled
How to Read a GLP-1 Trial Result Without Getting Misled If you’ve ever read a Phase 3 GLP-1 trial press release and walked away with a single headline number — ‘28.7% weight loss!’ — and then tried to figure out whether that number actually applied to people like you, you’ve encountered the gap between trial-result […]
Retatrutide for Athletes Worried About Lean Mass: What the Trial Data Shows
Retatrutide for Athletes Worried About Lean Mass: What the Trial Data Shows If you’re someone who has put serious work into building muscle — through years of resistance training, deliberate nutrition, or competitive sport — the idea of taking a drug that produces deep weight loss is uncomfortable. Most weight-loss interventions sacrifice some lean mass […]
Retatrutide for Patients with Type 2 Diabetes vs Obesity Alone: How the Trial Data Differs
Retatrutide for Patients with Type 2 Diabetes vs Obesity Alone: How the Trial Data Differs If you’ve followed retatrutide and noticed that the weight-loss numbers in different trials don’t match — 28.7% in TRIUMPH-4, 16.8% in TRANSCEND-T2D-1, an expected number somewhere in between for TRIUMPH-1 — you’re noticing a real and important pattern. The same […]
Will Retatrutide Carry a Black Box Warning? What the Trial Data Suggests
Will Retatrutide Carry a Black Box Warning? What the Trial Data Suggests If you’ve looked at the prescribing information for any FDA-approved GLP-1 drug — semaglutide, tirzepatide, dulaglutide, liraglutide — you’ve seen the same boxed warning at the top of the label, in bold, framed in a black border: a thyroid tumor warning based on […]
Why Retatrutide Trials Use Such a Slow Dose Escalation
Why Retatrutide Trials Use Such a Slow Dose Escalation If you’ve looked at the design of any modern incretin trial — semaglutide, tirzepatide, retatrutide — and noticed that participants don’t start at the target dose but instead climb up over weeks or months, that’s not a quirk. It’s a deliberate design choice that meaningfully shapes […]
Why Phase 3 Obesity Trials Take So Long — and Where Retatrutide Stands
Why Phase 3 Obesity Trials Take So Long — and Where Retatrutide Stands If you’ve ever wondered why obesity drugs take so long to reach patients — or why every story about retatrutide includes some version of ‘still in trials’ — there’s a real answer, and it’s not pharmaceutical-industry foot-dragging. Phase 3 obesity trials run […]
Retatrutide FDA Filing: Reading the Signals From Eli Lilly’s Pipeline
Retatrutide FDA Filing: Reading the Signals From Eli Lilly’s Pipeline If you’ve been trying to read the tea leaves on when retatrutide actually gets filed with the FDA — and what that filing will look like — you’re in good company. Pharmaceutical filing dates are rarely announced in advance. They have to be inferred from […]
TRIUMPH-2: What the Diabetes-Plus-Obesity Trial Adds to the Retatrutide Picture
TRIUMPH-2: What the Diabetes-Plus-Obesity Trial Adds to the Retatrutide Picture If you have type 2 diabetes and obesity, and you’ve been following the retatrutide pipeline for the trial that actually applies to you, the answer is TRIUMPH-2. It’s the larger and longer of the two Phase 3 retatrutide trials in adults with type 2 diabetes […]
TRIUMPH-5: The Trial That Will Actually Compare Retatrutide and Tirzepatide Head-to-Head
TRIUMPH-5: The Trial That Will Actually Compare Retatrutide and Tirzepatide Head-to-Head If you’ve been trying to figure out how retatrutide actually compares with tirzepatide — not via cross-trial guesswork, but in a real head-to-head trial — there’s exactly one Phase 3 trial designed to answer that question. It’s called TRIUMPH-5, and despite what the trial-numbering […]